Prozac adds indications
Executive Summary
Lilly's Prozac (fluoxetine) gets additional indications July 29 for panic disorder with or without agoraphobia, and for longer-term treatment of bulimia. Prozac previously had an indication for bulimia based on 16-week data; the longer-term indication is based on 52-week patient follow-up. The company submitted the supplemental applications in anticipation of having Prozac exclusivity through June 2004, but a court decision invalidating its longest-running patent allowed generics to enter in August 2001...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.